Filing Flows › Pharma-Bio Serv (PBSV) › Q4 FY24
Pharma-Bio Serv (PBSV) Q4 FY24 earnings results (fourth quarter fiscal 2024)
10-K filed Jan 29, 2025
Pharma-Bio Serv (PBSV) reported revenue of $2.3M for the fourth quarter fiscal 2024 (Q4 FY24), -35% from a year earlier and -4% from the quarter before. Operating margin was -6.6%, net earnings $16K (0.7% of revenue).
Pharma-Bio Serv, Q4 FY24: revenue $2.3M (-35% year over year), operating margin -6.6%, net earnings $16K, operating cash flow $78K. The chart follows the revenue to costs, profit and cash.
| Q4 FY24 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | -4% | -35% |
| Operating profit | −$154K | — | — |
| Net earnings | $16K | — | — |
| Operating cash flow | $78K | — | -75% |
What changed
Revenue was $2.3M in Q4 FY24, down 35% year over year and down 4% from the previous quarter.
Gross margin was 31.1%, up 5.3 points from a year earlier. Operating costs exceeded revenue by $154K, an operating margin of -6.6%. Operating expenses fell 10% while revenue fell 35%. Net earnings were $16K. Non-operating items added $139K, -938% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $78K (down 75% year over year), 487% of net earnings. Non-cash charges added back $6K of depreciation and amortization and $3K of share-based compensation. Working capital and other items added $53K. Capital expenditures of $157K exceeded it, leaving free cash flow of −$79K.
Questions
What was Pharma-Bio Serv's revenue in the fourth quarter fiscal 2024?
Pharma-Bio Serv (PBSV) reported revenue of $2.3M for the fourth quarter fiscal 2024 (Q4 FY24), -35% from a year earlier and -4% from the quarter before.
Was Pharma-Bio Serv profitable in the fourth quarter fiscal 2024?
Operating loss was $154K (-6.6% of revenue) and net earnings $16K.
Source: Pharma-Bio Serv 10-K on SEC EDGAR.